Publications in collaboration with researchers from Pfizer (United States) (2)

2024

  1. Safety and efficacy of tofacitinib for the treatment of patients with juvenile idiopathic arthritis: Preliminary results of an open-label, long-term extension study

    Annals of the Rheumatic Diseases

2021

  1. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial

    The Lancet, Vol. 398, Núm. 10315, pp. 1984-1996